Truqap could fill a prostate cancer gap
The AKT inhibitor prevails in hormone-sensitive disease, but other studies have been delayed.
Essa terminates an N-terminal journey
After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.
Ipsen casts doubt on Pfizer’s prostate plan
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
Is this the end for MacroGenics’ vobra-duo?
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
